DERMATA THERAPEUTICS, INC. Shareholders' Equity
DERMATA THERAPEUTICS, INC. (DRMA) had Shareholders' Equity of $3.49 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $3.49M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $6.41M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $6.22M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $3.96M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $3.49M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $6.41M 10-Q · filed 2026-08-11 |
| 2025-12-31 | $6.22M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $3.96M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $5.61M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $7.30M 10-Q · filed 2026-08-11 |
| 2024-12-31 | $1.56M 10-Q · filed 2026-08-11 |
| 2024-09-30 | $4.74M 10-Q · filed 2025-11-14 |
| 2024-06-30 | $3.32M 10-Q · filed 2025-11-14 |
| 2024-03-31 | $3.81M 10-Q · filed 2025-11-14 |
| 2023-12-31 | $6.36M 10-K · filed 2026-03-26 |
| 2023-09-30 | $6.41M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $8.03M 10-Q · filed 2024-11-13 |
| 2023-03-31 | $8.09M 10-Q · filed 2024-11-13 |
| 2022-12-31 | $6.02M 10-K · filed 2025-03-17 |
| 2022-09-30 | $7.47M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $9.66M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $7.85M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $10.11M 10-K · filed 2024-03-21 |
| 2021-09-30 | $12.49M 10-Q · filed 2022-11-10 |
| 2021-06-30 | -$505.80K 10-Q · filed 2022-11-10 |
| 2021-03-31 | $712.00K 10-Q · filed 2022-11-10 |
| 2020-12-31 | -$3.18M 10-K · filed 2023-02-21 |
| 2020-09-30 | -$2.78M 10-Q · filed 2021-11-15 |
| 2020-06-30 | -$2.20M 10-Q · filed 2021-11-15 |
| 2020-03-31 | -$1.63M 10-Q · filed 2021-11-15 |
| 2019-12-31 | -$210.16K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |